<DOC>
	<DOCNO>NCT01230736</DOCNO>
	<brief_summary>The purpose study assess safety efficacy change DuoTrav® prior bimatoprost 0.03 % /timolol 0.5 % ( use concomitantly fix combination ) pharmacotherapy uncontrolled patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Efficacy Changing DuoTrav From Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Must clinical diagnosis ocular hypertension , primary openangle pigment dispersion glaucoma eye . Must IOP 19 35 millimeter mercury ( mmHg ) ( time day ) least one eye ( would designate study eye ) . Must willing discontinue use ocular hypotensive medication ( ) prior receive study medication entire course study . Women pregnant lactating . Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity poor tolerance component DuoTrav® deem clinically significant opinion Principal Investigator . Corneal dystrophies either eye . Risk visual field visual acuity worsen consequence participation study , investigator 's best judgment . Bronchial asthma history bronchial asthma , bronchial hyperreactivity , severe chronic obstructive pulmonary disease would preclude safe administration topical betablocker . History severe allergic rhinitis . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>